Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tobradex AF · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tobradex AF | DRUG | - |
Inclusion Criteria: * Adult patients requiring cataract surgery Exclusion Criteria: * Age related
Tobradex AF is an investigational small molecule being developed by Alcon Inc. for use in cataract patients. It is currently in Phase 3 clinical development for this ophthalmic indication. The drug is being studied in a clinical trial setting to evaluate its effects in patients undergoing cataract treatment.
Tobradex AF is being developed by Alcon Inc., a company traded on the stock exchange under the ticker symbol ALC. Alcon is conducting clinical research on this investigational drug for the treatment of cataract patients. The company is responsible for the ongoing development and clinical trials of Tobradex AF.
Tobradex AF is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for use in cataract patients, and its Phase 3 trial has been completed. Further regulatory review would be required before any potential approval.
Tobradex AF has one completed Phase 3 clinical trial registered under NCT00473070, titled "A Clinical Study of Tobradex AF." This trial enrolled 900 participants with cataract in the United States. The study was randomized and double-blind, though it did not use a control group. Participants were aged 18 years and older.
Tobradex AF is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for cataract patients. The drug's Phase 3 trial has been completed, but it has not yet received regulatory approval. Alcon Inc. would need to submit and receive approval from regulatory authorities before Tobradex AF could be marketed.